FDA Drug Shortage Alert: Propofol Supply Update (April 2026)
Propofol remains on the FDA shortage list through Q2 2026. Korva Pharma maintains available inventory — here is what practices need to know.
Propofol (generic and branded) is currently listed on the FDA Drug Shortages database due to manufacturing disruptions at two major production facilities. The shortage has been ongoing since January 2026 and is expected to persist through mid-Q2.
Who is Affected
Oral surgery practices, ambulatory surgery centers (ASCs), and dental anesthesia providers are most directly impacted. Propofol is a first-line induction agent for procedures requiring general anesthesia or deep sedation, and there are limited direct substitutes at equivalent cost and safety profiles.
Current Supply Status at Korva Pharma
We have secured available inventory of propofol (10 mg/mL, 20 mL and 50 mL vials) from verified lots. Existing customers should contact their representative to confirm allocation. New customers can apply online — approval typically takes 1–2 business days.
What to Do Now
- Audit your current on-hand supply. Calculate days-on-hand based on your procedure volume.
- Place orders earlier than usual. Shortage conditions mean lead times are less predictable.
- Document your ordering pattern. DEA and state regulators expect documentation of medical necessity during shortage periods.
- Consider etomidate as a backup for induction in ASA I–II patients where clinically appropriate — but confirm with your anesthesiologist first.
Regulatory Note
During a declared shortage, the FDA exercises enforcement discretion on certain compounded formulations. However, compounded propofol from 503A and 503B facilities carries different liability profiles than FDA-approved product. We only supply FDA-approved lots.
Questions?
Contact us at info@heliospharma.com or apply to become a customer if you are not already set up with a distributor who can serve your controlled substance and injectable needs.